Effects of a newly bronchodilator for lung hyperinflation and exercise tolerance in patients with mild to moderate stable COPD

Effects of a newly bronchodilator for lung hyperinflation and exercise tolerance in patients with mild to moderate stable COPD - Effects of a newly bronchodilator in patients with mild to moderate stable COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009857

Enrollment

Registered

2013-01-24

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Placebo-Placebo Indacaterol-Placebo Glycopyrronium bromide-Placebo Indacaterol-Glycopyrronium bromide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinical stable mild to moderate COPD patients with age more than 40 years 2. A post-bronchodilator forced expiratory volume in 1 second (FEV1) /forced vital capacity (FVC) of < 0.7. a post-bronchodilator forced expiratory volume <120% and >50% of the predicted normal value (i.e. stage Ior II) 3. Patients who provided written informed consent

Exclusion criteria

Exclusion criteria: 1.other respiratory disease 2.severe other orgen disease 3.subjects who have been treated with LABA and/or LAMA in 2 weeks 4.subjects who have been shown exacervation. 5.subjects who doctors regarded unsuitable for this trial 6.subjects who had allergy for these drugs.

Design outcomes

Primary

Measure	Time frame
Respiratory function	—

Countries

Japan

Contacts

Public ContactTakashi Kinoshita

Kurume University School of Medicine Department of Medicine, Division of Respiratory, Neurology and Rheumatology

0942-35-3311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026